Clinical Trial Update: Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself [Phase 2]

View source ↗

Summary

A Phase 2 trial for a second-line therapy in age-related macular degeneration patients not responding to Lucentis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Vitreous -Retina- Macula Consultants of New York | Conditions: Age Related Macular Degeneration | Phase 2 | Status: WITHDRAWN